BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30884972)

  • 1. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 4. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
    Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
    BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
    Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
    Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
    Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
    Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN
    Panos GD; Arruti N; Patra S
    Eur J Ophthalmol; 2021 Mar; 31(2):620-629. PubMed ID: 31906704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
    Currie CJ; Holden SE; Berni E; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
    Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
    Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
    Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
    Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
    Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
    Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
    Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results.
    Chronopoulos A; Chronopoulos P; Ashurov A; Korb C; Pfeiffer N; Hattenbach LO
    Eur J Ophthalmol; 2022 Jan; 32(1):443-449. PubMed ID: 33601897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
    Syed YY
    Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
    Holden SE; Currie CJ; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.